`

About EveliQure

Company overview

EveliQure Biotechnologies was founded in 2012 by Tamás Henics MD, PhD, Eszter Nagy MD, PhD, Gábor Nagy MD, PhD, and Zoltán Dobai, MSc, to develop novel vaccines for the prevention of diarrheal diseases.

EveliQure is an innovative biotech company developing novel vaccines for the prevention of diarrheal diseases that are highly relevant for travelers and young children living in developing countries.

It is widely accepted that vaccination would be the most effective way to address this high unmet medical need; yet, no vaccines are currently available.

EveliQure developed a novel vaccine technology platform based on a live attenuated Shigella strain that is able to induce broad protection against shigellosis caused by different species and serotypes. This vaccine strain serves as a platform to achieve broad coverage of diarrheal pathogens by the designed expression of non-shigella derived antigens. Shigetec™, the first generation vaccine candidate targets Shigella and Enterotoxigenic E. coli (ETEC), the two major causes of diarrhea.


Management Team

Tamás Henics, MD, PhD
Co-Founder and Chief Scientific Officer

Tamás Henics has decades long experience in research leadership in academic and biotechnology setting. Dr. Henics received his MD degree in Hungary in 1990 and a PhD degree in molecular immunology and cell biology in 1996.

read more


Gábor Somogyi, MD, MBA
Chief Executive Officer

Gábor Somogyi is a dedicated, experienced business professional with passion for life sciences and business. He has over a decade experience in business management including successful start-up and project management backed up with strong scientific background.

read more

Frank Malinoski, MD, PhD
Chief Medical Officer

Dr. Malinouski has extensive, over twenty years of vaccine experience in preclinical, clinical, regulatory, medical affairs (post-licensure), safety, and business development, including board membership. He received a BA degree from Colby College in 1976 and trained in microbiology (PhD; Rutgers University, 1981) and medicine (MD; Albany Medical College, 1985).

read more



Advisory Board

Tamás Henics, MD, PhD
Co-Founder and Chief Scientific Officer

Tamás Henics has decades long experience in research leadership in academic and biotechnology setting. Dr. Henics received his MD degree in Hungary in 1990 and a PhD degree in molecular immunology and cell biology in 1996.

Henics worked in several academic institutes in the US (Dartmouth College and Medical School, Hanover, NH; Roswell Park Cancer Institute, Buffalo, NY) and in Hungary (Dept. of Medical Microbiology and Immunology, Medical University of Pécs) before he joined Intercell (Vienna, Austria) in 1999. He had a major contribution to the development of the bacterial antigen discovery platform and antimicrobial peptide based vaccine adjuvants. From 2005 he continued his research activity on adjuvants in the Dept. of Genetics at the Marx F. Perutz Laboratories in Vienna and supported the understanding of mode of action of synthetic vaccine adjuvant developed by Intercell. In 2010 he joined the RT-EUROPE Research Laboratories in Hungary as Head of Research, where he worked until the foundation of EveliQure. Dr. Henics published his research work in > 40 peer-reviewed research journals in the last 12 years mainly in vaccination related topics and he is inventor on several patents.

×

Gábor Somogyi, MD, MBA
Chief Executive Officer

Gábor Somogyi is a dedicated, experienced business professional with passion for life sciences and business. He has over a decade experience in business management including successful start-up and project management backed up with strong scientific background. He completed his medical degree in Hungary (1998) and holds a business degree from the business school of the New York State University, NY (2003). Dr. Somogyi had been the managing director of the breakthrough technology start-up called Colorfront. They were the world-wide leader in their business segment at the time, won the Oscars and were acquired by a large multinational company. Additionally, he has over a decade project and contracts management experience in multinational companies in megaprojects mainly in the Middle East. His strong scientific interest and medical background coupled with his MBA and business experience contributes to company success.

×

Frank Malinoski MD, PhD
Chief Medical Officer

Dr. Malinouski has extensive, over twenty years of vaccine experience in preclinical, clinical, regulatory, medical affairs (post-licensure), safety, and business development, including board membership. He received a BA degree from Colby College in 1976 and trained in microbiology (PhD; Rutgers University, 1981) and medicine (MD; Albany Medical College, 1985).

Throughout his career he held numerous executive positions such as Director of Clinical Research at Lederle-Praxis Biologicals, Senior Vice President of Clinical and Medical Affairs at Nabi Biopharmaceuticals, Vice President of Medical Affairs at Wyeth, Chief Medical Officer and Senior Vice President of Development for Oxxon Therapeutics, Inc, and Vice President and then Senior Vice President of Medical and Scientific Affairs at MedImmune, LLC. He served on the board of LigoCyte Pharmaceuticals, Inc., a biotech vaccine company in Bozeman, MT from March 2008 to March 2009 and is involved with the North Carolina Biotechnology Center in Wilmington, NC. Dr. Malinoski has authored or co-authored multiple scientific and vaccine related publications, and is a member of several editorial boards.

×

Eszter Nagy, MD, PhD
Co-Founder, board member, advisor

Co-founder and CSO, Arsanis, Inc.

Former SVP of Research, Intercell AG (now Valneva)

szöveg

×

Gábor Nagy, MD, PhD
Co-Founder, scientific advisor

Dept Head of Microbiology and In Vivo Models, Arsanis

Former group leader at Intercell AG (now Valneva)

szöveg

×
EveliQure Biotechnologies GmbH

Campus Vienna Biocenter
Vienna Austria

© 2015 EveliQure Biotechnologies GmbH